At Spermotile, we're pioneering a breakthrough in Assisted Reproductive Therapy. Our focus is on identifying the highest quality sperm from semen samples, a critical step in the ART process. With a pending patent, we're now delving into nanoscale sperm motion analysis and advanced kinematic parameters to ensure the best outcomes for fertility treatments.
Immediate outcome and impact:
1. Securing the IP of Spermotile has kick started.
2. The FTO analysis has revealed the competition and indicated the IP family that we need to build
3. The project has led us into Nordic Innovation House's REACH program, for which RCN has covered the course fees and UiT has awarded us an additional 190 KNOK for the travel and participation in the REACH program
4. The market analsys has revealed the market needs and market drivers in India and Europe.
The technology will be valuable for actors within both reproduction research and fertility clinics. Additionally, Spermotile will have significant value for people experiencing infertility, as it can increase the chances of successful fertilization and ultimately lead to the birth of a healthy child, while reducing the need for unnecessary and invasive treatments, and minimizing emotional and psychological stress for the soon-to-be parents.
The use of Spermotile will have economic benefits, as it can reduce the need for costly and invasive fertility treatments, which can save couples and insurance companies significant amounts of money. Moreover, successful pregnancies resulting from ARTs can reduce the need for expensive neonatal and pediatric medical care, which can also have a positive impact on the economy. Furthermore, Spermotile can contribute to the overall well-being of society by reducing the stigma associated with infertility and fertility treatments.